MX2021000792A - Metodo de uso de un coagonista de gip/glp1 para la diabetes. - Google Patents
Metodo de uso de un coagonista de gip/glp1 para la diabetes.Info
- Publication number
- MX2021000792A MX2021000792A MX2021000792A MX2021000792A MX2021000792A MX 2021000792 A MX2021000792 A MX 2021000792A MX 2021000792 A MX2021000792 A MX 2021000792A MX 2021000792 A MX2021000792 A MX 2021000792A MX 2021000792 A MX2021000792 A MX 2021000792A
- Authority
- MX
- Mexico
- Prior art keywords
- gip
- glp
- peptide
- provides methods
- diabetes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona métodos para tratar la diabetes tipo 2 (T2D) usando un nuevo régimen de dosificación de un péptido GIP:GLP-1 que tiene una relación de potencia agonista del receptor GIP:GLP-1 que es de aproximadamente 2.5:1 a aproximadamente 10:1 GIP a GLP-1. Además, la presente invención proporciona métodos para tratar la T2D usando un nuevo régimen de dosificación de un péptido GIP:GLP-1 que tiene una relación de potencia agonista del receptor GIP:GLP-1 que es de aproximadamente 2.5:1 a aproximadamente 5:1 de GIP a GLP-1. Además, la presente invención proporciona métodos para inducir la remisión de T2D usando un nuevo régimen de dosificación de un péptido GIP:GLP-1. La presente invención también proporciona métodos para tratar la obesidad usando un nuevo régimen de dosificación de un péptido GIP:GLP-1.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862702180P | 2018-07-23 | 2018-07-23 | |
US201862730562P | 2018-09-13 | 2018-09-13 | |
US201862740640P | 2018-10-03 | 2018-10-03 | |
PCT/US2019/042824 WO2020023388A1 (en) | 2018-07-23 | 2019-07-22 | Method of using a gip/glp1 co-agonist for diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021000792A true MX2021000792A (es) | 2021-06-15 |
Family
ID=67544389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021000792A MX2021000792A (es) | 2018-07-23 | 2019-07-22 | Metodo de uso de un coagonista de gip/glp1 para la diabetes. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230293638A1 (es) |
EP (1) | EP3826662A1 (es) |
JP (3) | JP2021530544A (es) |
KR (1) | KR20210024081A (es) |
CN (1) | CN112469431A (es) |
AU (1) | AU2019309798A1 (es) |
BR (1) | BR112020026020A2 (es) |
CA (1) | CA3107108A1 (es) |
IL (2) | IL308674A (es) |
MA (1) | MA53378A (es) |
MX (1) | MX2021000792A (es) |
SG (1) | SG11202100116TA (es) |
WO (1) | WO2020023388A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202216746A (zh) | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型glp-1/gip雙重促效劑 |
BR112023000270A2 (pt) | 2020-07-22 | 2023-01-31 | Novo Nordisk As | Composto, composição farmacêutica, e, peptídeo |
AU2021361263A1 (en) | 2020-10-17 | 2023-02-16 | Sun Pharmaceutical Industries Limited | GLP-1/GIP dual agonists |
JP2024508745A (ja) * | 2021-02-17 | 2024-02-28 | イーライ リリー アンド カンパニー | Gip/glp1デュアルアゴニスト治療方法 |
TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
CN116854805B (zh) * | 2023-09-05 | 2023-12-15 | 杭州湃肽生化科技有限公司 | 替尔泊肽的制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA028665B1 (ru) | 2012-05-03 | 2017-12-29 | Зилэнд Фарма А/С | Соединения - двойные агонисты gip-glp-1 и способы |
WO2015022420A1 (en) * | 2013-08-16 | 2015-02-19 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
US20170112897A1 (en) * | 2015-10-23 | 2017-04-27 | Cedars-Sinai Medical Center | Methods for treating brain insulin resistance |
TWI622596B (zh) * | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
JOP20210016A1 (ar) * | 2018-07-23 | 2021-01-21 | Lilly Co Eli | مركبات مساعدة مشتركة gip/glp1 |
-
2019
- 2019-07-22 MA MA053378A patent/MA53378A/fr unknown
- 2019-07-22 CA CA3107108A patent/CA3107108A1/en active Pending
- 2019-07-22 WO PCT/US2019/042824 patent/WO2020023388A1/en unknown
- 2019-07-22 IL IL308674A patent/IL308674A/en unknown
- 2019-07-22 IL IL280159A patent/IL280159B2/en unknown
- 2019-07-22 JP JP2021503596A patent/JP2021530544A/ja active Pending
- 2019-07-22 BR BR112020026020-7A patent/BR112020026020A2/pt unknown
- 2019-07-22 US US17/260,279 patent/US20230293638A1/en active Pending
- 2019-07-22 KR KR1020217002278A patent/KR20210024081A/ko not_active Application Discontinuation
- 2019-07-22 MX MX2021000792A patent/MX2021000792A/es unknown
- 2019-07-22 SG SG11202100116TA patent/SG11202100116TA/en unknown
- 2019-07-22 AU AU2019309798A patent/AU2019309798A1/en not_active Abandoned
- 2019-07-22 EP EP19749938.7A patent/EP3826662A1/en active Pending
- 2019-07-22 CN CN201980048741.8A patent/CN112469431A/zh active Pending
-
2022
- 2022-09-12 JP JP2022144239A patent/JP2022177118A/ja active Pending
-
2024
- 2024-02-13 JP JP2024019543A patent/JP2024056852A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL280159B2 (en) | 2024-05-01 |
CN112469431A (zh) | 2021-03-09 |
MA53378A (fr) | 2021-06-02 |
CA3107108A1 (en) | 2020-01-30 |
BR112020026020A2 (pt) | 2021-03-23 |
JP2021530544A (ja) | 2021-11-11 |
JP2024056852A (ja) | 2024-04-23 |
US20230293638A1 (en) | 2023-09-21 |
AU2019309798A1 (en) | 2021-02-11 |
WO2020023388A1 (en) | 2020-01-30 |
SG11202100116TA (en) | 2021-02-25 |
IL308674A (en) | 2024-01-01 |
JP2022177118A (ja) | 2022-11-30 |
KR20210024081A (ko) | 2021-03-04 |
EP3826662A1 (en) | 2021-06-02 |
IL280159B1 (en) | 2024-01-01 |
IL280159A (en) | 2021-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021000792A (es) | Metodo de uso de un coagonista de gip/glp1 para la diabetes. | |
MX2021015328A (es) | Agonistas del receptor del peptido-1 similar al glucagon. | |
PH12017501252A1 (en) | Gip and glp-1 co-agonist compounds. | |
CL2020002033A1 (es) | Conjugado persistente de triple activador que activa el receptor de glucagón, glp-1 u gip. (divisional solicitud 201801795) | |
EA201991345A1 (ru) | Новые соединения в качестве пептидных тройных агонистов рецепторов glp1/глюкагона/gip | |
MX2021008965A (es) | Proceso para preparar un agonista dual de gip/glp1. | |
MX2021015160A (es) | Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso. | |
MX2020012064A (es) | Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r. | |
EA201592281A1 (ru) | Новые модуляторы рецептора glp-1 | |
MX2020008387A (es) | Usos terapeuticos de agonistas glp1r. | |
MX2019006427A (es) | Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip. | |
MX2021005725A (es) | Tratamiento de la obesidad y sus complicaciones. | |
MX2021012871A (es) | Generacion de polipeptidos derivados de anticuerpos mediante intercambio de cadenas polipeptidicas. | |
CR20210200A (es) | Formulación de anticuerpos | |
MX2021004351A (es) | Metodo para el tratamiento de miastenia grave. | |
MX2022011730A (es) | Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r. | |
PH12021551243A1 (en) | Oxyntomodulin peptide analog formulations | |
EA202092810A1 (ru) | Способ применения ко-агониста gip/glp1 при диабете | |
MX2022015577A (es) | Proceso para preparar un agonista dual glp-1/glucagon. | |
MX2021007444A (es) | Proteina biespecifica. | |
PH12021551210A1 (en) | Anti-igf-i receptor humanized antibody | |
MX2020010715A (es) | Sintesis de lixisenatida con taponamiento. | |
MX2019013750A (es) | Un metodo para producir ranibizumab humanizado recombinante replegado. | |
MX2021015930A (es) | Composiciones farmaceuticas para peptidos co-agonistas de glucagon y glp-1. | |
EA202192442A1 (ru) | Способ получения агонистов рецептора глюкагоноподобного пептида-1 (glp-1) и их аналогов |